RAY1225
GIP/GLP-1 · s.c. every 2 weeks · Raynovent
Summary
- Also known as
- Raynovent
- Mechanism
- GIP/GLP-1
- Route
- s.c. every 2 weeks
- Company
- Raynovent
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 REBUILDING-2 positive (9 mg every 2 weeks: −22.2 % at 52 weeks, topline Oct 2026); licensed to Qilu verify
- Next milestone
- NDA in China
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Positive phase 3 REBUILDING-2 (topline Oct 2026) | |
| T2D | 2 phase 3 ongoing | Phase 3 registered on ClinicalTrials.gov | |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REBUILDING-1 (RAY1225, NCT06254261) | 3 mg Q2W | obesity china | 24 | 172 | — | —−10.1 % vs −3.5 % estimand not specified | — | — | — | — | — | — | — | press release |
| REBUILDING-1 (RAY1225, NCT06254261) | 6 mg Q2W | obesity china | 24 | 172 | — | —−13.0 % vs −3.5 % estimand not specified | — | — | — | — | — | — | — | press release |
| REBUILDING-1 (RAY1225, NCT06254261) | 9 mg Q2W | obesity china | 24 | 172 | — | —−15.1 % vs −3.5 % estimand not specified | — | — | — | — | — | — | — | press release |
| SHINING-1 (RAY1225, NCT06254274) | 3 mg Q2W | t2d china | 24 | 231 | — | — | −1.7 vs −0.2 | — | — | — | — | — | — | congress |
| SHINING-1 (RAY1225, NCT06254274) | 6 mg Q2W | t2d china | 24 | 231 | — | — | −2.0 vs −0.2 | — | — | — | — | — | — | congress |
| SHINING-1 (RAY1225, NCT06254274) | 9 mg Q2W | t2d china | 24 | 231 | — | — | −2.1 vs −0.2 | — | — | — | — | — | — | congress |
| SHINING-1 (RAY1225, NCT06254274) | 12 mg Q2W | t2d china | 24 | 231 | — | — | −2.3 vs −0.2 | — | — | — | — | — | — | congress |
| Shining-1 (T2D) | RAY1225 15 mg every 2 weeks | t2d china | 24 | — | — | — | −2.8 vs −0.2 | — | — | — | — | — | −7.8 vs +0.0 | verified |
| REBUILDING-2 (RAY1225, NCT06893016) | 9 mg Q2W | obesity china | 52 | 641 | −22.3 % | −22.2 % | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- RAY1225 15 mg every 2 weeks: Weight change not given in the abstract; SBP is placebo-adjusted
Verbatim quotes from the source (10)
- RAY1225 15 mg every 2 weeks · hba1c · Abstract, Results
-2.76% (-3.25 to -2.26) in the 3 mg, 6mg, 9mg, 12mg and 15 mg, respectively
- 9 mg Q2W · weight_tp · HKEX filing
9mg 组体重较基线降低 22.24%,经安慰剂校正后降低 20.46%
- 9 mg Q2W · weight_eff · HKEX filing
补充分析(假想策略)RAY1225 注射液 9mg 组体重较基线降低 22.30%,经安慰剂校正后降低 20.50%
- 3 mg Q2W · weight_unsp · HKEX filing
治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
- 6 mg Q2W · weight_unsp · HKEX filing
治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
- 9 mg Q2W · weight_unsp · HKEX filing
治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
- 3 mg Q2W · hba1c · abstract
The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
- 6 mg Q2W · hba1c · abstract
The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
- 9 mg Q2W · hba1c · abstract
The changes in HbA1c from baseline to week 24 were -1.66% (95% CI -1.88 to -1.45), -2.04% (-2.26 to -1.82), -2.14% (-2.36 to -
- 12 mg Q2W · hba1c · abstract
1.92) , -2.34% (-2.56 to -2.12), -2.76% (-3.25 to -2.26) in the 3 mg, 6mg, 9mg, 12mg and 15 mg, respectively, versus -0.25% (-0.43 to -0.07)
Registered trials (3)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07139535 A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | T2D | Phase 3 | not yet recruiting | 2025-08 → 2026-12 | 350 | not yet recruiting | NCT07139535 |
| NCT07139548 A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes | T2D | Phase 3 | not yet recruiting | 2025-08 → 2026-12 | 600 | not yet recruiting | NCT07139548 |
| NCT06893016 Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight | Obesity | Phase 3 | recruiting | 2025-06 → 2026-06 | 640 | recruiting | NCT06893016 |
Primary sources
- Leili Gao et al. RAY1225, a bi-weekly fully biased GLP-1/GIP receptor agonist in type 2 diabetes: a phase 2 trial in Chinese adults (Shining-1). Abstract 16. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: OP 03 GLP-1 and friends: new clinical insights]
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd64086.
- Raynovent / Zhongsheng. 众生药业 (002317.SZ) 关于控股子公司一类创新药RAY1225注射液减重III期临床试验获得顶线分析数据结果的公告 (2026-068) [HKEX filing]. 2026-10-08. Available from: http://static.cninfo.com.cn/finalpage/2026-10-09/1225597551.PDF
- Raynovent / Zhongsheng. 众生药业 (002317.SZ) 关于控股子公司一类创新药RAY1225注射液II期临床试验获得顶线分析数据结果的公告 (2025-045) [HKEX filing]. 2025-05-06. Available from: http://static.cninfo.com.cn/finalpage/2025-05-07/1223477369.PDF
How to cite this page
Cite the primary publication for any single result; every value above links to it.